Loading clinical trials...

Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung

A PHASE 2, OPEN-LABEL TRIAL OF DACOMITINIB (PF-00299804) IN SELECTED PATIENTS WITH ADVANCED ADENOCARCINOMA OF THE LUNG

NCT00818441•Pfizer

View on ClinicalTrials.gov

Summary

This study will explore the safety and efficacy of the oral PanHER inhibitor PF-00299804 in patients with adenocarcinoma of the lung who are either non-smokers (\<100 cigarette, cigar or pipe lifetime) or former light smokers ( less than 10 pack-years and stopped at least 15 years) or have known EGFR activating mutation; or patients with HER 2 amplification or mutation.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Advanced adenocarcinoma of lung, measurable disease
•Non-smoker, or former light (less than 10 pack years and stopped at least 15 years); OR
•patients with known EGFR activating mutation regardless of smoking status
•ECOG(Eastern Cooperative Oncology Group) 0-1.
•Cohort B (select sites only): patients with HER2 amplified or HER2 mutation-positive NSCLC; may have had prior therapy

Exclusion Criteria

•Active brain metastases
•Prior systemic therapy for advanced disease in Cohort A only. Cohort B can have had any number of prior lines of systemic therapy.
•known EGFR wild type NSCLC

Locations (41)

University of California, Irvine

Orange, California, United States

Chao Family Comprehensive Cancer Center UC Irvine Medical Center

Orange, California, United States

Bay Area Cancer Research Group, LLC

Pleasant Hill, California, United States

Pacific Cancer Care

Salinas, California, United States

San Francisco General Hospital

San Francisco, California, United States

University of Colorado Clinical Trials Office (CTO)

Aurora, Colorado, United States

University of Colorado Hospital

Aurora, Colorado, United States

Florida Cancer Specialists

Fort Myers, Florida, United States

National Institutes of Health National Cancer Institute

Bethesda, Maryland, United States

Massachusetts General Hospital

Boston, Massachusetts, United States

Key Dates

Start Date

March 11, 2009

Primary Completion Date

April 27, 2012

Completion Date

April 30, 2015

Last Updated

January 8, 2019

Enrollment

119

ACTUAL participants

Conditions

Carcinoma, Non-small Cell

Interventions

Dacomitinib (PF-00299804)

DRUG

Dacomitinib (PF-00299804)

DRUG

A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors

NCT06549816

Carcinoma, Non-Small Cell LungSquamous Cell Carcinoma of Head and Neck+4 more

View study

WITHDRAWNPHASE1/PHASE2

A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy

NCT04151563

Carcinoma, Non-small Cell Lung Cancer

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 8, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung

Inclusion Criteria

Exclusion Criteria

A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors

A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy

Efficacy and Safety of BAI Combined With DEB-BACE of EqualSpheres in the Treatment of Advanced NSCLC

Metabolomic Analysis of Lung Cancer

NEUWAVE Flex Microwave Ablation System in the Ablation of Primary Soft Tissue Lesions of the Lung

Docetaxel Versus Intercalated Erlotinib-docetaxel in Patients With Relapsed EGFR Wild Type, ALK Negative Non Squamous Cell Carcinoma